Charles Russell Speechlys advises Vapotherm on the acquisition of Solus Medical

Charles Russell Speechlys has advised Vapotherm, Inc., a global medical technology company, on the acquisition of its former UK distributor Solus Medical Limited.  Solus is based in Scotland and the acquisition provides Vapotherm with a UK-based direct sales organisation.

Vapotherm, Inc. (NYSE: VAPO) is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA, which develops innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders. Over 1.7 million patients have been treated with Vapotherm’s proprietary Hi-VNI Technology, which delivers non-invasive ventilatory support for spontaneously breathing patients and is a front-line tool for relieving respiratory distress, including hypercapnia, hypoxemia, and dyspnea.

Anthony Ten Haagen, VP Legal Affairs & Compliance at Vapotherm, commented “Daniel Rosenberg, Jonathan Steele, and the entire Charles Russell Speechlys team were invaluable in guiding us through this acquisition quickly and efficiently, and we look forward to continuing to work with them through the integration effort”.

Daniel Rosenberg, Corporate Partner at Charles Russell Speechlys, said “we were delighted to work with Vapotherm on this first acquisition following its IPO on NYSE in last November and we look forward to working with the Vapotherm team as they continue to expand internationally”.

The Charles Russell Speechlys team was led by Daniel Rosenberg and included Jonathan Steele and Tertius Alberts (Corporate), Caroline Young (Commercial/Healthcare) and Becky Lawton and Josie Macleod (Employment).  The team worked with Brodies on Scottish law issues.